Michael O'Donnell

Harvard University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Jacob Taylor

NYU Langone Health

UNITED STATES

View details

Vignesh Packiam

Associate Professor of Urology

Rutgers Cancer Institute of New Jersey

UNITED STATES

View details

Ian McElree

Vanderbilt University Medical Center

UNITED STATES

View details

Yousef Zakharia

The University of Iowa

UNITED STATES

View details

Riitta Lassila

FINLAND

View details

Ryan Steinberg

Clinical Assistant Professor

University of Iowa Healthcare

UNITED STATES

View details

Courtney Yong

Indiana University Health

UNITED STATES

View details

Yi Luo

University of Iowa Healthcare

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael O'Donnell

Research Interests

Explore related searches

Contact this professor

Articles (19)

Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor

Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer

Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.

Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

Re: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022;82:602–10

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS

Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.

Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Navigating the Treacherous Waters of Bacillus Calmette-Guérin Failure

Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.

Alternative Instillation Techniques of Sequential Intravesical Gemcitabine and Docetaxel for NMIBC.

Real-word efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.

US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin-Unresponsive and Bacillus Calmette-Guérin-Exposed Nonmuscle-Invasive Bladder Cancer.

Stimulated whole blood cytokine/chemokine responses are associated with interstitial cystitis/bladder pain syndrome phenotypes and features of nociplastic pain: a MAPP research network study.

A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report

Collaborators (8)

Jacob Taylor

Vignesh Packiam

Ian McElree

Yousef Zakharia

Riitta Lassila

Ryan Steinberg

Courtney Yong

Yi Luo

Make your next move.